ArticleAngewandte Chemie (International ed. in English)2026
De Novo Discovery of Nonstandard Thioisoindole-Bridged Bicyclic Peptides Targeting Traf2- and NCK-Interacting Kinase.
Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Macrocyclization strategies that generate conformationally constrained peptide scaffolds within nucleotide-encoded library screening platforms have significantly advanced the discovery of de novo bioactive peptides. We previously reported ribosomal synthesis of topologically defined thioisoindole-bridged bicyclic (TiB) peptides, but complete conversion required overnight incubation. Here, we reengineer the key ribosomally incorporated substrate to accelerate TiB formation to full conversion within 2 h. This was followed by a streptavidin-based pulldown step to efficiently remove linear species and purify the desired TiB peptides. The optimized chemistry was incorporated into the RaPID (Random nonstandard peptides integrated discovery) system to enable de novo identification of TiB peptide ligands. As a proof of concept, two complementary TiB libraries were screened against Traf2- and NCK-interacting kinase (TNIK). Of the five TiB candidates identified, four exhibited nanomolar affinity for TNIK (best K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.